Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
599,986.800000 Euro
Request Reference:
1411024
Request Name:
Ocrelizumab 300 mg/10 ml Sol inj Fr 10 ml IV CPA 2023/491 Nova qt
Phase:
Tendering Phase
State:
Awarded
Description:
1411024 Ocrelizumab 300 mg/10 ml Sol inj Fr 10 ml IV CPA 2023/491 Nova qt
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
O1030 - OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]
-
180
(
Days
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Rua Conceição Fernandes 4434-502 Vilar de Andorinho Vila Nova de Gaia Área Metropolitana do Porto PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
6/14/2024 8:24 AM
(UTC +1 hour)
National official publishing date and time (DR):
9/4/2023 8:17 AM
(UTC +1 hour)
Due datetime for receiving replies:
6/18/2024 12:10 PM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
Yes
Seriousness of the offer
Compliance
Yes
Stability and Quality of Works
% of contract value
2
Warranty Start Date
-
Warranty End Date
-
Extra-contractual civil liability
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Convite .pdf
Convite .pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
O1030 - OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]
Base Price
599 986,800000
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
116812037
OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]
120,000000
PT1.UMT.4520
Buyer Comment:
500233810 | Roche - Farmacêutica Química, Lda. | CPA:2023491/150/0367 | NºAIM:5737523;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Automático
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - O1030 - OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
Gráfico/Fórmula
1.
Preço
(Tipo de Dados: Preço)
Permitir intervenção manual na avaliação?
Sim
Não
Nome
Descrição
Valor
Minimum price of all proposals
Reply with the lowest price of all qualified replies
-
Visualizar
Price in analysis
Price in analysis
-
Visualizar
Preço
100%
Fórmula: Min(Pi)
Normas de desempate
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...